Vical, Inc.

VICL NASDAQ
1.140
+0.020
+1.79%
Closed 16:00 05/17 EDT
Open
1.110
Prev Close
1.120
High
1.140
Low
1.110
Volume
63.82K
Avg Vol (3M)
192.01K
52 Week High
1.780
52 Week Low
0.8500
% Turnover
0.28%
Market Cap
26.02M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Related

Webull offers Vical, Inc. VICL stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients; an ongoing Phase I program of VL-2397 for invasive fungal infections, and completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant.
MORE >

Recently

Name
Price
%Change